Supplemental Figure S4. (A) BrdU incorporation into doxorubicin treated or untreated endothelial cells infected with E4ORF1 or vector control (MSCV-puro) measured by flow cytometry. Cells were pulsed with BrdU for 24hrs before measurement. (B) E4ORF1 or vector control endothelial cells were treated with doxorubicin to induce senescence and fixed and stained for senescence-associated-beta-galactosidase 5 days after treatment. Percentage of B-galactosidase positive cells is shown. (C) BrdU incorporation into doxorubicin and/or rapamycin treated or untreated endothelial cells measured by flow cytometry. Cells were pulsed with BrdU for 24hrs before measurement. (D) IL-6 transcript levels in E4ORF1 or control endothelial cells at various times after treatment with doxorubicin. h=hour, d=day. **P<.05